GlassScriptPhysician profile
Youssef A Hanalla
NPI 1437127545
$3,069.13
in general payments reported to CMS, 2019-2025
30 companies · $82.52 in 2025
The $82.52 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $505 · 2021: $1,056 · 2022: $926 · 2023: $79.51 · 2024: $105 · 2025: $82.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $266.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $390.37 | 2021-2022 | |
| Brainlab, INC. | $388.13 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $283.52 | 2022-2025 | |
| Janssen Biotech, INC. | $281.87 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $195.21 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $194.82 | 2019-2022 | |
| Amgen INC. | $154.02 | 2021-2022 | |
| Karyopharm Therapeutics INC. | $123.73 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $99.00 | 2019 | |
| Genentech USA, INC. | $82.17 | 2021-2022 | |
| Astellas Pharma US INC | $80.19 | 2022-2023 | Padcev |
| Eisai INC. | $79.81 | 2021-2023 | |
| Daiichi Sankyo INC. | $74.40 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $71.48 | 2021-2022 | |
| Glaxosmithkline, LLC. | $67.91 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Morphosys, US INC. | $56.84 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $51.55 | 2022 | |
| Blue Earth Diagnostics | $50.90 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.27 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $41.34 | 2021-2022 | |
| Dova Pharmaceuticals | $37.73 | 2021 | |
| Boston Scientific Corporation | $37.13 | 2019 | |
| Incyte Corporation | $35.72 | 2021 | |
| Gilead Sciences, INC. | $32.51 | 2021 | |
| Genzyme Corporation | $23.14 | 2022 | |
| Merck Sharp & Dohme LLC | $22.17 | 2022 | |
| Q Biomed INC. | $20.97 | 2020 | |
| Dendreon Pharmaceuticals LLC | $19.60 | 2021 | |
| Novocure INC. | $17.97 | 2021 | |
| Varian Medical Systems, INC. | $12.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Youssef Hanalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.